Zobrazeno 1 - 10
of 15
pro vyhledávání: '"F. Cheldieva"'
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/90bc55017a4748b3839665ef209cb647
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/efb88ce37e0841119b37cde00ee815ab
Publikováno v:
Thursday 06 October 2022 from 13:00 to 14:10.
Publikováno v:
Thursday 06 October 2022 from 13:00 to 14:10.
Publikováno v:
Annals of the Rheumatic Diseases. 81:670.1-670
BackgroundThe study of other non-criteria antiphospholipid antibodies (aPL) may improve the stratification of patients with antiphospholipid syndrome (APS) and assist in the interpretation of conflicting results on aPL testing.ObjectivesTo determine
Autor:
A. Borisova, T. Lisitsyna, D. Veltishchev, T. Reshetnyak, O. Seravina, O. Kovalevskaya, F. Cheldieva
Publikováno v:
Annals of the Rheumatic Diseases. 81:1373.1-1373
BackgroundSuicidal ideations in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) patients are associated with stress related depressive and anxiety disorders and can lead to higher mortality rates.ObjectivesTo describe the rates
Publikováno v:
Annals of the Rheumatic Diseases. 81:1188.1-1189
BackgroundThromboinflammation is a pathological process that is associated with uncontrolled inflammation, leading to hypercoagulability and thrombotic complications. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are prototyp
Publikováno v:
Annals of the Rheumatic Diseases. 81:1374.2-1375
BackgroundThe role of antiphospholipid antibodies (aPL) not included in the International Classification Criteria for the verification of APS continues to be discussed.ObjectivesTo determine the clinical significance of IgG antibody for domain 1 β2-
Publikováno v:
Annals of the Rheumatic Diseases. 80:605.2-606
Background:The study of antiphospholipid antibodies (aPL), not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood.Objectives:To determine the frequency of detecti
Publikováno v:
Annals of the Rheumatic Diseases. 80:643.2-644
Background:In more than 40% of cases, systemic lupus erythematosus (SLE) is associated with the presence of highly positive antiphospholipid antibodies, with 50-70% of patients developing antiphospholipid syndrome (APS) over the next 10 years of the